Keywords: positive, ph, ii, data, esperion, etc-216, promising

Positive Ph II data for Esperion's ETC-216

Article | 10 November 2003

Promising new data have been published for USA-based EsperionTherapeutics' anti-atherosclerosis drug, ETC-216, in the November 5 issue of the Journal of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pfizer

Go to company listing